Advertisement

Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent Type in Patients With ST-Segment Elevation Myocardial Infarction Randomized to Bare Metal or Drug-Eluting Stenting During Primary Percutaneous Coronary Intervention

      It is unknown whether high-sensitivity C-reactive protein (hs-CRP) predicts outcome depending on implanted stent type. We investigated the prognostic value of hs-CRP in relation to type of stent implanted in patients with ST-segment elevation myocardial infarction (STEMI). Immediately before primary percutaneous coronary intervention (pPCI), 301 patients had blood drawn. Patients were categorized according to hs-CRP levels and combination of hs-CRP (≤2 vs >2 mg/L) and stent type (bare metal stent [BMS] vs drug-eluting stent [DES]). Hs-CRP >2 mg/L (median, hazard ratio 2.7, 95% confidence interval 1.3 to 5.6, p = 0.007) and the combined variable of hs-CRP >2 mg/L and BMS (hazard ratio 2.4, 95% confidence interval 1.2 to 4.5, p = 0.006) independently predicted the composite end point of death and MI at 36-month follow-up. There was a significant interaction (p = 0.006) for hs-CRP and stent type. Survival analysis demonstrated significant differences for occurrence of death and MI: 4.8% in BMS + CRP ≤2 mg/L, 11.9% in DES + CRP ≤2 mg/L, 17.6% in DES + CRP >2 mg/L, and 27.9% in BMS + CRP >2 mg/L. None of the 14 stent thromboses occurred in patients with BMS + CRP ≤2 mg/L. In conclusion, preprocedure hs-CRP predicts outcome after pPCI in patients with STEMI. Our hypothesis-generating data indicate that BMS implantation should be preferred when hs-CRP is ≤2 mg/L and DES when hs-CRP is >2 mg/L to decrease long-term adverse outcomes including stent thrombosis in patients with STEMI treated with pPCI. These findings need confirmation in larger randomized clinical trials.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Costa M.A.
        • Simon D.I.
        Molecular basis of restenosis and drug-eluting stents.
        Circulation. 2005; 111: 2257-2273
        • Inoue T.
        • Node K.
        Molecular basis of restenosis and novel issues of drug-eluting stents.
        Circ J. 2009; 73: 615-621
        • Welt F.G.P.
        • Rogers C.
        Inflammation and restenosis in the stent Era.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1769-1776
        • Chen J.P.
        • Hou D.
        • Pendyala L.
        • Goudevenos J.A.
        • Kounis N.G.
        Drug-eluting stent thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited.
        JACC Cardiovasc Interv. 2009; 2: 583-593
        • Ortolani P.
        • Marzocchi A.
        • Marrozzini C.
        • Palmerini T.
        • Saia F.
        • Taglieri N.
        • Baldazzi F.
        • Silenzi S.
        • Bacchi-Reggiani M.L.
        • Guastaroba P.
        • Grilli R.
        • Branzi A.
        Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention.
        Eur Heart J. 2008; 29: 1241-1249
        • Park D.W.
        • Yun S.C.
        • Lee J.Y.
        • Kim W.J.
        • Kang S.J.
        • Lee S.W.
        • Kim Y.H.
        • Lee C.W.
        • Kim J.J.
        • Park S.W.
        • Park S.J.
        C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation.
        Circulation. 2009; 120: 1987-1995
        • Kelbaek H.
        • Thuesen L.
        • Helqvist S.
        • Clemmensen P.
        • Klovgaard L.
        • Kaltoft A.
        • Andersen B.
        • Thuesen H.
        • Engstrom T.
        • Botker H.E.
        • Saunamaki K.
        • Krusell L.R.
        • Jorgensen E.
        • Hansen H.H.
        • Christiansen E.H.
        • Ravkilde J.
        • Kober L.
        • Kofoed K.F.
        • Terkelsen C.J.
        • Lassen J.F.
        Drug-eluting versus bare metal stents in patients with ST-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial.
        Circulation. 2008; 118: 1155-1162
        • Kaltoft A.
        • Kelbaek H.
        • Thuesen L.
        • Lassen J.F.
        • Clemmensen P.
        • Kløvgaard L.
        • Engstrøm T.
        • Bøtker H.E.
        • Saunamäki K.
        • Krusell L.R.
        • Jørgensen E.
        • Tilsted H.H.
        • Christiansen E.H.
        • Ravkilde J.
        • Køber L.
        • Kofoed K.F.
        • Terkelsen C.J.
        • Helqvist S.
        Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) trial.
        J Am Coll Cardiol. 2010; 56: 641-645
        • Ridker P.M.
        Clinical application of C-reactive protein for cardiovascular disease detection and prevention.
        Circulation. 2003; 107: 363-369
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • Rifai N.
        • Rose L.M.
        • McCabe C.H.
        • Pfeffer M.A.
        • Braunwald E.
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Yang E.Y.
        • Nambi V.
        • Tang Z.
        • Virani S.S.
        • Boerwinkle E.
        • Hoogeveen R.C.
        • Astor B.C.
        • Mosley T.H.
        • Coresh J.
        • Chambless L.
        • Ballantyne C.M.
        Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study.
        J Am Coll Cardiol. 2009; 54: 2388-2395
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • Steg P.G.
        • Morel M.A.
        • Mauri L.
        • Vranckx P.
        • McFadden E.
        • Lansky A.
        • Hamon M.
        • Krucoff M.W.
        • Serruys P.W.
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Joner M.
        • Finn A.V.
        • Farb A.
        • Mont E.K.
        • Kolodgie F.D.
        • Ladich E.
        • Kutys R.
        • Skorija K.
        • Gold H.K.
        • Virmani R.
        Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
        J Am Coll Cardiol. 2006; 48: 193-202
        • Bisoendial R.J.
        • Kastelein J.J.P.
        • Levels J.H.M.
        • Zwaginga J.J.
        • van den Bogaard B.
        • Reitsma P.H.
        • Meijers J.C.M.
        • Hartman D.
        • Levi M.
        • Stroes E.S.G.
        Activation of inflammation and coagulation after infusion of C-reactive protein in humans.
        Circ Res. 2005; 96: 714-716
        • Danenberg H.D.
        • Szalai A.J.
        • Swaminathan R.V.
        • Peng L.
        • Chen Z.
        • Seifert P.
        • Fay W.P.
        • Simon D.I.
        • Edelman E.R.
        Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice.
        Circulation. 2003; 108: 512-515
        • Pasceri V.
        • Willerson J.T.
        • Yeh E.T.H.
        Direct proinflammatory effect of C-reactive protein on human endothelial cells.
        Circulation. 2000; 102: 2165-2168
        • Gurbel P.A.
        • Bliden K.P.
        • Kreutz R.P.
        • Dichiara J.
        • Antonino M.J.
        • Tantry U.S.
        The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting.
        Platelets. 2009; 20: 97-104
        • Yun K.
        • Jeong M.
        • Oh S.
        • Rhee S.
        • Park E.
        • Lee E.
        • Yoo N.
        • Kim N.H.
        • Ahn Y.
        • Jeong J.W.
        Response of high-sensitivity C-reactive protein to percutaneous coronary intervention in patients with acute coronary syndrome.
        Heart Vessels. 2009; 24: 175-180
        • Gach O.
        • Legrand V.
        • Biessaux Y.
        • Chapelle J.P.
        • Vanbelle S.
        • Pierard L.A.
        Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris.
        Am J Cardiol. 2007; 99: 31-35
        • Dibra A.
        • Ndrepepa G.
        • Mehilli J.
        • Dirschinger J.
        • Pache J.
        • Schühlen H.
        • Schömig A.
        • Kastrati A.
        Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents.
        Am J Cardiol. 2005; 95: 1238-1240
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard BrG.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
        Lancet. 2009; 373: 1175-1182
        • Colley C.M.
        • Fleck A.
        • Goode A.
        • Muller B.
        • Myers M.
        Early time course of the acute phase protein response in man.
        J Clin Pathol. 1983; 36: 203-207
        • Kushner I.
        • Broder M.
        • Karp D.
        Control of the acute phase response.
        J Clin Invest. 1978; 61: 235-242
        • Aggarwal A.
        • Schneider D.J.
        • Terrien E.F.
        • Gilbert K.E.
        • Dauerman H.L.
        Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response.
        J Thromb Thrombolysis. 2003; 15: 25-31
        • El-Mokhtari N.
        • Zschernitz S.
        • Sebens S.
        • Simon-Herrmann G.
        • Krüger D.
        Cardiac release and kinetics of cytokines after elective bare metal coronary stenting.
        J Thromb Thrombolysis. 2010; 30: 391-397